IMMUNITYBIO, INC. Debt and Equity Securities, Realized Gain (Loss)
IMMUNITYBIO, INC. (IBRX) reported Debt and Equity Securities, Realized Gain (Loss) of $173.00 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Income Statement › Other Income
us-gaap:DebtAndEquitySecuritiesRealizedGainLoss · last filed 2021-11-12
- IMMUNITYBIO, INC. debt and equity securities, realized gain (loss) for the quarter ending 2021-09-30 was $0.00.
- IMMUNITYBIO, INC. debt and equity securities, realized gain (loss) for the quarter ending 2020-09-30 was -$2.00K.
| Period end | Debt and Equity Securities, Realized Gain (Loss) 3 month | Debt and Equity Securities, Realized Gain (Loss) 6 month | Debt and Equity Securities, Realized Gain (Loss) 9 month |
|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $173.00K 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $173.00K 10-Q · filed 2021-08-12 | ||
| 2020-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$2.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |